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The synthesis and preliminary biological evaluation of neutral and cationic platinum derivatives of 41 
chiral 1-(1-naphthyl)ethylamine are reported, namely cycloplatinated neutral complexes [PtCl{(R or S)-42 
NH2CH(CH3)C10H6}-(L)] [L = SOMe2 (1-R or 1-S), L = PPh3 (2-R or 2-S), L = P(4-FC6H4)3 (3-R), 43 
L = P(CH2)3N3(CH2)3 (4-R)], cycloplatinated cationic complexes [Pt{(R)-H2CH(CH3)C10H6}{L}]Cl 44 
[L = Ph2PCH2CH2PPh2 (5-R), L = (C6F5)2PCH2CH2P-(C6F5)2 (6-R)] and the Pt(II) coordination 45 
compound trans-[PtCl2{(R)-NH2CH(CH3)C10H6}2] (7-R). The X-ray molecular structure of 7-R is 46 
reported. The cytotoxic activity against a panel of human adenocarcinoma cell lines (A-549 lung, MDA-47 
MB-231 and MCF-7 breast, and HCT-116 colon), cell cycle arrest and apoptosis, DNA interaction, 48 
topoisomerase I and cathepsin B inhibition, and Pt cell uptake of the studied compounds are presented. 49 
Remarkable cytotoxicity was observed for most of the synthesized Pt(II) compounds regardless of (i) the 50 
absolute configuration R or S, and (ii) the coordinated/cyclometallated (neutral or cationic) nature of the 51 
complexes. The most potent compound 2-R (IC50 = 270 nM) showed a 148-fold increase in potency 52 
with regard to cisplatin in HCT-116 colon cancer cells. Preliminary biological results point out to 53 
different biomolecular targets for the investigated compounds. Neutral cyclometallated complexes 1-R 54 
and 2-R, modify the DNA migration as cisplatin, cationic platinacycle 5-R was able to inhibit 55 
topoisomerase I-promoted DNA supercoiling, and Pt(II) coordination compound 7-R turned out to be 56 
the most potent inhibitor of cathepsin B. Induction of G-1 phase (2-R and 5-R), and S and G-2 phases 57 
(6-R) arrests are related to the antiproliferative activity of some representative compounds upon A-549 58 




It is well known that cisplatin is an efficient anticancer drug through formation of platinum–DNA 63 
adducts that are capable of inducing programmed cell death.1 Since double-helical DNA has a chiral 64 
structure, the stereochemistry of the adducts formed with complexes containing enantiomeric ligands 65 
can influence the antitumor activity.2 66 
Early studies carried out for compounds cis-[PtX2A2] (A = amine ligand and X = anionic ligand), 67 
indicated that the activity decreases in the order A = NH3 > RNH2 > R2NH, and, therefore, most 68 
investigations concerning chiral monodentate ligands were restricted to platinum complexes with 69 
primary amines. The negligible difference generally observed for the biological activities of the 70 
enantiomers was related to the free rotation that offset any stereospecificity in the interactions with 71 
biological substrates. The degree of rotational freedom can be reduced using chelate ligands, an 72 
outstanding example being oxaliplatin, a third generation anti-cancer drug containing trans-1R,2R-73 
diaminocyclohexane. The lower activity of the trans-1S,2S and cis-1R,2S isomers are attributed to the 74 
distinct stereochemical structures of the complexes.3–5 Moreover, it is interesting to point out that three 75 
out of the six platinum compounds (namely oxaliplatin, lobaplatin and heptaplatin) approved for clinical 76 
use have a chiral structure (see Chart 1).1,5 77 
On the other hand, cycloplatinated complexes have raised great interest as anticancer agents,6,7 and 78 
compounds containing either bidentate [C,N]8–21 or terdentate [C,N,N′]22–27 ligands have been tested 79 
against tumor cells with very promising results. The high stability of these compounds allows them to 80 
reach the cell unaltered. Furthermore, the labile ligands favor covalent coordination to DNA as for 81 
cisplatin while the aromatic groups in the cyclometallated ligand might favour intercalative binding to 82 
DNA through π–π stacking. 83 
In spite of the continuous progress in the field of cyclometallation, the cycloplatination of primary 84 
amines remains relatively unexplored.28–31 Since it has been claimed that cycloplatinated amines 85 
represent a suitable organometallic scaffold for cytostatic drugs,31 and in view of the small number of 86 
cyclometallated platinum compounds containing a primary amine described so far, we decided to 87 
prepare new neutral and cationic platinum derivatives of chiral 1-(1-naphthyl)ethylamine and to study 88 
their biological activities. These compounds combine several features that make them very suitable 89 
candidates for biological studies: a platinum center, a cyclometallated chiral primary amine, the 90 
possibility of being involved in hydrogen bonds through the NH2 group, ancillary ligands with different 91 
stereo-electronic properties and, for the neutral compounds, a labile chlorido ligand. 92 
93 
RESULTS AND DISCUSSION 94 
 95 
Synthesis of the cycloplatinated compounds 96 
The preparation of parent compound [PtCl{(R)-NH2CH(CH3)-C10H6}(SOMe2)] (1-R) from the 97 
platinum(II) precursor cis-[PtCl2(SOMe2)2] has been previously reported.30 The success of the 98 
synthesis under mild conditions has been related to the presence of both a naphthyl substituent and a 99 
methyl group at the α-position of the amine in agreement with the fact that the cyclometallation of 100 
amines is promoted by steric encumbrance, as established for palladium analogues.32 In particular, 101 
substitution of the carbon at the α position to the amino group plays a pivotal role related to a noticeable 102 
decrease in entropic requirements.33 The lability of the dimethylsulfoxide ligands allows for the 103 
synthesis of neutral compound [PtCl{(R)-NH2CH(CH3)C10H6}(PPh3)] (2-R) upon reaction with PPh3, 104 
while ionic compound [Pt{(R)-NH2CH(CH3)C10H6}-{Ph2PCH2CH2PPh2}]Cl (5-R) containing a 105 
chelating diphosphine is obtained upon reaction with 1,2-bis(diphenylphosphine) ethane.30 106 
As shown in Scheme 1, the same synthetic strategies were used in this work to expand the family of 1-107 
(1-naphthyl)ethylamine derivatives including neutral complexes [PtCl{(R)-NH2CH(CH3)C10H6}{P(4-108 
FC6H4)3}] (3-R) and [PtCl{(R)-NH2CH-(CH3)C10H6}{P(CH2)3N3(CH2)3)}] (4-R), as well as the 109 
ionic compound [Pt{(R)-NH2CH(CH3)C10H6}{(C6F5)2PCH2CH2P(C6F5)2}]Cl(6-R). Interest in 110 
fluorinated derivatives 3-R and 6-R is related to the fact that fluoro substituents have been proposed as 111 
an excellent choice to modify the electronic properties and hydrophobicity of related cycloplatinated 112 
complexes34 while keeping stereochemical changes to a minimum. In addition, introduction of 113 
fluorinated groups would permit the use of 19F NMR spectroscopy in the characterization of the 114 
compounds.35 On the other hand, the water-soluble monodentate phosphine 1,3,5-triaza-7-115 
phosphaadamantane (PTA) in compound 4-R is a useful hydrophilic co-ligand, which may impart a pH-116 
dependent behavior in biologically active transition metal compounds.36–40 Compounds 3-R, 4-R and 117 
6-R were prepared from compound [PtCl{(R)-NH2CH(CH3)C10H6}(SOMe2)] (1-R) after stirring an 118 
equimolar mixture of this compound and the corresponding mono or diphosphine in acetone at room 119 
temperature. Under the reaction conditions, 4-R precipitates as a white solid, very slightly soluble in 120 
most common solvents including water, in spite of the ability of PTA to solubilize transition metal 121 
complexes in the aqueous phase.37,38 In contrast, precipitation of 3-R and 6-R from the reaction 122 
mixture requires the addition of hexane. 123 
The new compounds 3-R, 4-R and 6-R were characterised by elemental analyses and 1H, 19F (3-R and 124 
6-R), 31P and 195Pt NMR spectra. NMR data were collected in CDCl3 except for 4-R that could only 125 
be dissolved in d6-dmso. 1H-NMR data are in agreement with the proposed structures; in particular, 126 
coupling of the amino protons to platinum was only observed for compound 6-R (2JH–Pt = 75.2 Hz) 127 
while for compound 3-R the aromatic proton at the ortho position was coupled to platinum (3JH–Pt = 128 
52.0 Hz). For compounds 3-R and 4-R the JP–Pt values obtained from both 31P and 195Pt NMR spectra 129 
indicate that the phosphine ligand is trans to the amino group. For compound 6-R, two resonances are 130 
observed in the 31P NMR spectrum with 1JP–Pt values of 1594.0 and 3878.8 Hz. The higher J value is 131 
assigned to the phosphorus atom trans to the amino and the lower one to that trans to the metallated 132 
carbon in agreement with the expected values.30,41 The 19F NMR spectrum of compound 3-R displays 133 
one multiplet corresponding to the three equivalent para-fluoro substituents of the phosphine; in 134 
contrast, a much higher complexity is obtained for the spectrum of compound 6-R in which three sets of 135 
four signals in the regions −124 to −129 ppm assigned to 8 Fortho, −140 to −143 ppm assigned to 4 136 
Fpara, and −155 to −157 ppm assigned to 8 Fmeta are observed. These values are in good agreement 137 
with those previously reported for complexes containing diphosphines bearing pentafluorophenyl groups 138 
and suggest the non-equivalence of the four pentafluorophenyl groups.35,42 All 195Pt chemical shift 139 
values, collected in Table 1 along with those for previously reported compounds 1-R, 2-R and 5-R, are 140 
in the expected range for square-planar platinum(II) compounds with the corresponding donor atom set 141 
[C, N, Cl, P] for compounds 3-R and 4-R and [C, N, P, P] for compound 6-R.43 142 
In order to complete this study, the coordination compound [PtCl2{(R)-NH2CH(CH3)C10H6}2] (7-R), 143 
containing two non-cyclometallated amine ligands, was also prepared upon reaction of two equivalents 144 
of the amine with K2PtCl4 in water–methanol mixtures at room temperature. Both 1H and 195Pt NMR 145 
spectra of the latter compound indicate the presence of a single isomer, and the δ(195Pt) value is in the 146 
range expected for a platinum(II) coordinated to two Cl and two N donor atoms. Based on previous 147 
results for similar compounds, 29,44 and taking into account the steric bulk of the amine ligands, it is 148 
expected that the amine ligands are mutually trans. Suitable crystals of 7-R were grown from 149 
dichloromethane–methanol at room temperature and they were analyzed by X-ray diffraction. The 150 
obtained molecular structure confirms both the mutual trans arrangement of the amine ligands and the R 151 
configuration of both chiral carbons (see Fig. 1). As shown in Fig. S1–S3,† the molecules are associated 152 
in dimers, with a Pt⋯Pt short contact of 3.222 Å, and the dimers are arranged in columnar stacks. It is 153 
interesting to point out that, although previous structure–activity relationship studies suggest a higher 154 
activity for cis-configured compounds, in the last few decades many trans platinum compounds have 155 
been shown to be cytotoxic.45 Finally, in order to address the influence of the chirality upon the 156 
biological properties of the compounds, the corresponding enantiomers 1-S and 2-S derived from (S)-157 
NH2CH-(CH3)C10H6 were also prepared using identical procedures as those described for 1-R and 2-R 158 
30 and the compounds were characterized by NMR spectra. 159 
 160 
Biological studies. Antiproliferative assay 161 
Human lung, breast and colon cancer cell lines (A-549, MDA-MB-231 and MCF-7 and HCT-116, 162 
respectively) were used to test the cytotoxic activity of the platinum(II) complexes 1-R–7-R and 1-S–2-163 
S. Cisplatin, as a positive control, was evaluated under identical experimental conditions. The effects of 164 
the assayed metallacycles on the growth of the selected cell lines were evaluated after 72 h and the 165 
obtained IC50 values are listed in Table 2. For comparison purposes, these results are represented as a 166 
bar graph in Fig. 2. 167 
Data presented in Table 2 and Fig. 2 show that the investigated compounds exhibit variable selectivity 168 
against the adenocarcinoma cell lines tested. Several complexes showed greater cytotoxicity 169 
effectiveness than cisplatin. Taking into account the cisplatin resistant HCT-116 colon cancer cell line, 170 
the following trend can be derived for complexes 1-R–7-R, 1-S–2-S and cisplatin:  171 
 172 
2-R > 6-R > 5-R > 7-R > 2-S > 3-R > 1-R > 1-S > cisplatin    4-R 173 
 174 
Considering the R configured neutral platinacycles 1-R–4-R, it is noteworthy that complex 2-R with a 175 
Pt–P bond (L = PPh3) exhibits lower IC50 values than compound 1-R with a Pt–S bond (L = SOMe2). 176 
Actually compound 2-R is 4.5–52 times, depending on the cell line selected, more potent than complex 177 
1-R. Furthermore compound 2-R also showed a lower IC50 value than compounds 3-R [L = P(4-178 
FC6H4)3] and 4-R [L = P(CH2)3N3(CH2)3] both with a Pt–P bond. Interestingly, platinacycle 2-R 179 
(IC50 = 270 nM) showed a 148-fold increase in potency as cytotoxic agent with regard to cisplatin in 180 
HCT-116 (cisplatin resistant) colon adenocarcinoma cells (Table 2). The platinacycle 2-R was up to 21-181 
fold more potent as a cytotoxic agent than the corresponding cyclometallated palladium(II) complex, 182 
previously described in our research group, in A-549 lung human cancer cells.46 This may be due to the 183 
greater lability and faster hydrolysis rate of palladium complexes compared to their platinum 184 
analogues.47 Surprisingly, no cytotoxic activity was observed for the PTA derivative 4-R at 100 μM 185 
concentration, a fact that can be related to the low solubility of this compound, or to the steric 186 
encumbrance of the PTA ligand. The absolute configuration (R/S) of the cyclometallated ligand [1-(1-187 
naphthyl)ethylamine] does not play a role in the target molecular discrimination between the two pairs 188 
of enantiomers 1-R vs. 1-S and 2-R vs. 2-S.2 Platinacycles 1-R and 1-S, and 2-R and 2-S, in pairs 189 
exhibited comparable IC50 values in the four adenocarcinoma cell lines assayed. 190 
The ionic complexes with a chelating diphosphine 5-R and 6-R showed remarkable potency against the 191 
four adenocarcinoma cell lines tested and were up to 22- and 25-fold more potent as cytotoxic agents 192 
than cisplatin. Nevertheless, we did not find the expected increase in potency34 in the complex 193 
exhibiting the fluorinated chelating diphosphine (6-R) with regard to the complex containing the non-194 
fluorinated one (5-R). Finally, a notable potency was detected for the coordination compound 7-R 195 
containing two non-cyclometallated amine ligands. Compound 7-R (IC50 = 4.5 μM) showed 196 
approximately a 9-fold increase in potency as a cytotoxic agent with regard to cisplatin in HCT-116 197 
(cisplatin resistant) colon cancer cell lines (Table 2). 198 
 199 
Effect of compounds 2-R, 5-R and 6-R on cell cycle distribution 200 
Cell cycle dysregulation is considered to be one of the main hallmarks of cancer cells and those proteins 201 
that control the critical events of cell cycle have been proposed as useful antitumor targets.48–50 There 202 
are three main phases in the cell cycle distribution: quiescent and gap1 (G0 and G1), synthesis (S), gap2 203 
and mitosis (G2 and M) phases. The effect of the compounds 2-R, 5-R and 6-R were studied over A-549 204 
cells, by incubating them with these compounds at a concentration equal to their IC50 values, for 72 205 
hours and the results were analyzed by FACS (Fluorescence Activated Cell Sorting) using propidium 206 
iodide (PI) staining to quantify their DNA content. The results of the analysis (Fig. 3) show that all the 207 
three compounds affect the cell cycle distribution at different levels. Compounds 2-R and 5-R show an 208 
increase of about 29% and 21%, respectively, of the cell population at the G1 checkpoint with a 209 
concomitant decrease at the S and G2 phases. In contrast, compound 6-R shows an increase of the cell 210 
populations of about 17% and 33%, respectively at the S and G2 phases. 211 
 212 
Effect of compounds 2-R, 5-R and 6-R on apoptosis induction 213 
The antiproliferative effects of these compounds were further tested for their effects in apoptosis 214 
induction in A-549 cells. Because cancer is characterized by uncontrolled cellular proliferation, there is 215 
a considerable interest in chemotherapeutic-induced apoptosis. By using fluorescein-labeled annexin V 216 
(AV–FITC, annexin V-fluorescein isothiocyanate) and PI (propidium iodide), the apoptosis-inducing 217 
properties of 2-R, 5-R and 6-R in A-549 cells were examined by performing flow cytometry. In the 218 
earlier events of the apoptotic process, plasma membrane asymmetry is lost, accompanied by 219 
phosphatidylserine (PS) translocation from the inner to the outer membrane. 51 Thus PS is exposed to 220 
the external environment of the cell and can bind to the annexin V-FITC conjugate with a high 221 
affinity.51,52 During the late apoptotic and necrotic stages, the cell membranes lose their integrity, 222 
allowing PI to access the nucleus and intercalate between DNA bases. The differential distribution 223 
between non-apoptotic cells (annexin V− and PI−), early apoptotic (annexin V+ and PI−) and necrotic or 224 
later apoptotic (PI+) cells were achieved by FACS analysis using annexin V-FITC staining and PI 225 
accumulation. 226 
The results (Fig. 4) from the apoptosis assay do not show a drastic effect of the compounds 2-R, 5-R and 227 
6-R at their IC50 concentrations (9.3, 1.2 and 4.6 μM) for 72 h upon the A-549 cells. However there are 228 
some notable effects, such as an increase in early apoptosis induction by all the three compounds, 229 
especially 5 and 7 times increase by 2-R and 6-R, respectively, and more than 3 times increase in 230 
necrosis induction by 2-R, with respect to the untreated control cells. Therefore compounds 2-R and 6-R 231 
at their IC50 concentrations (9.3 and 4.6 μM), generated early apoptosis in 6.9 and 9.0% respectively of 232 
the total cells population, as compared to the 1.3% of the early apoptotic cells in the untreated controls, 233 
and 2-R generated late apoptosis/necrosis in 8.9% of the total cell population, as compared to the 2.6% 234 
of the late apoptotic/ necrotic cells in the untreated controls. 235 
All these results strongly suggest that the main antiproliferative activities shown by the compounds are 236 
by cell cycle arrest, in G1 phase for 2-R and 5-R, and in S and G2 phases for 6-R. 237 
 238 
DNA interaction 239 
The interaction of cyclometallated complexes 1-R–6-R and 1-S–2-S and coordination compound 7-R 240 
with DNA was studied by their ability to modify the electrophoretic mobility of the supercoiled closed 241 
circular (sc) and the open circular (oc) forms of pBluescript SK+ plasmid DNA. The sc form usually 242 
moves faster due to its compact structure. To provide a basis for comparison, incubation of DNA with 243 
cisplatin and ethidium bromide (EB) was also performed using the same concentrations and conditions.  244 
Platinacycles 1-R and 2-R induce significant changes in the mobility of plasmid DNA (Fig. 5). Complex 245 
1-R shows a coalescence point at 100 μM and positive supercoiling at higher concentrations. 246 
Platinacycle 2-R greatly alter the mobility of plasmid DNA; at 50 μM concentration the rate of 247 
migration of the supercoiled band (sc) decreased to that of the nicked relaxed band (oc) and above this 248 
concentration the DNA is no longer visible. Platinacycles 1-S and 2-S were much less efficient in 249 
removing the supercoils from DNA than the corresponding enantiomers R (Fig. 5). 250 
It is noteworthy that the complex 2-R with one of the lowest IC50 value of the investigated compounds 251 
showed the greatest alteration on plasmid DNA mobility. On the basis of the gel mobility shift assay, it 252 
is hypothesized that platinacycles 1-R and 2-R alter the DNA tertiary structure by the same mechanism 253 
as the standard reference, cisplatin. In contrast with these findings, compounds 3-R–7-R (Fig. 5) were 254 
not effective at all for removing the supercoils of plasmid DNA, pointing to a different mechanism of 255 
action or an alternative biomolecular target. 256 
To evaluate the ability of the investigated platinum(II) complexes to intercalate into DNA, a 257 
topoisomerase-based gel assay was performed with complexes 3-R–7-R. Supercoiled pBluescript 258 
plasmid DNA was incubated in the presence of topoisomerase I at increasing concentrations of 259 
compounds 3-R–7-R. The results are given in Fig. 6 and they show that 5-R prevent unwinding of DNA 260 
by the action of topoisomerase I, indicating that this compound is either intercalator or topoisomerase I 261 
inhibitor. Ethidium bromide (EB), used as an intercalator control, prevents the shift of supercoiled DNA 262 
into a relaxed state. Complexes 3-R, 4-R, 6-R, and 7-R do not prevent unwinding of DNA by the action 263 
of topoisomerase I, indicating that these compounds are neither intercalators nor topoisomerase I 264 
inhibitors.53 265 
To dilucidate whether platinacycle 5-R is a DNA-intercalator or a topoisomerase I inhibitor, relaxed 266 
pBluescript plasmid DNA was incubated in the presence of topoisomerase I at increasing concentrations 267 
of compound 5-R. It is well known that compounds that are topoisomerase I inhibitors will prevent 268 
topoisomerase I from changing the state of the relaxed DNA into a supercoiled state, whereas in the 269 
presence of an intercalator such as ethidium bromide, topoisomerase I will convert the relaxed DNA into 270 
a supercoiled state.54 The results are given in Fig. 7 and show that 5-R prevents unwinding of DNA by 271 
the action of topoisomerase I, indicating that this compound is the inhibitor of topoisomerase I. In higher 272 
eukaryotes, DNA topoisomerases I are essential enzymes whose main role is to relieve DNA 273 
supercoiling (torsional tension) ahead of replication and transcription complexes.55,56 Nowadays 274 
topoisomerase I is considered an important molecular target for anticancer drug development. The 275 
anticancer activity of trinuclear (TriplatinNC, TriplatinNC-A)57 and naphthoquinone58 Pt(II) 276 
complexes, and luminescent cyclometallated Pt(II)59 compounds have being associated with their 277 
ability to inhibit topoisomerase I. Interestingly, in topoisomerase-based gel assay, complex 5-R acts as 278 
topoisomerase I inhibitor like camptothecin, a well-known topoisomerase I inhibitor.58 279 
Cathepsin B inhibition 280 
Cathepsin B is a cysteine metalloprotease highly upregulated in a wide variety of cancers by 281 
mechanisms ranging from gene amplification to post-transcriptional modification. The exact role of 282 
cathepsin B in solid tumors has yet to be defined, but it has been proposed to participate in metastasis, 283 
angiogenesis, and tumor progression. Recently, compounds based on palladium, platinum, ruthenium, 284 
rhenium, gold and tellurium were shown to be effective inhibitors of cathepsin B.60 In addition, an 285 
excellent correlation between cathepsin B inhibition and cytotoxicity for some dinuclear biphosphine 286 
palladacycles61 and mononuclear platinacycles containing a fluorinated phosphine34 has been reported. 287 
In spite of these later results, we have recently reported53,62 that a series of cyclopalladated and 288 
cycloplatinated benzophenone imines were not efficient inhibitors of cathepsin B, although showing in 289 
vitro high cytotoxicity. 290 
We have determined the cathepsin B inhibition activity for compounds 1-R–7-R and 1-S–2-S and the 291 
results are given in Table 3. All the compounds with the exception of compound 4-R, which was not 292 
cytotoxic in the antiproliferative assay, inhibited cathepsin B in a dose dependent manner. Inhibition of 293 
cathepsin B with IC50 values below 50 μM was achieved for compounds 1-R, 1-S, 6-R and 7-R. The 294 
non-cyclometallated trans-Pt(II) compound 7-R turned out to be the most potent (IC50 = 17 μM) of the 295 
studied compounds inhibiting cathepsin B in vitro and showed also a quite high cytotoxic activity. For 296 
instance, in MDA-MB-231 breast adenocarcinoma cell line complex 7-R showed an IC50 of 1.9 μM in 297 
the viability assay. This is noteworthy taking into account that not always the cathepsin B inhibition 298 
properties of metallodrugs correlate with their antiproliferative activity.63 On the other hand, the trans-299 
platinum(II) compound 7-R did not modify the DNA tertiary structure and therefore may act on 300 
alternative biological targets in addition to cathepsin B.64 It have been reported that trans-platinum 301 
compounds show a biological behavior rather different from that of cisplatin (ability to form structurally 302 
different DNA adducts, different reactivity in front of cellular components such as glutathione, HMG 303 
proteins, DNA repair proteins, etc.) and hence these compounds may be the key to overcoming intrinsic 304 
or acquired resistance to cisplatin.64,65 305 
 306 
Cell accumulation 307 
Cellular uptake is considered an important issue concerning the cytotoxicity of platinum compounds. It 308 
is believed to be dependent of both passive diffusion and active transport.66 The inhibition of drug 309 
accumulation and increase of efflux have been directly related to mechanisms of acquired resistance to 310 
cisplatin.67 A high cellular uptake of structurally different palladium68,69 and platinum58,70,71 311 
compounds by several human cancer cell lines has been reported. Furthermore, within a series of 312 
complexes the highest cellular accumulation is in line with the highest cytotoxic activity.58,69–71 313 
The cellular accumulation of platinum was used as a measure of the cellular accumulation of compounds 314 
1-R–7-R and 1-S–2-S (mole of Pt per cell × 10−16) and cisplatin was used as the reference compound. 315 
Table 4 illustrates cellular accumulation of the nine tested compounds and cisplatin over 4 h, as applied 316 
to the breast cancer cell line MDA-MB-231. 317 
Accumulation of the studied platinum complexes in MDA-MB-231 breast cancer cells was considerably 318 
greater than that of cisplatin for all the compounds tested and follows the order: 319 
 320 
7-R > 1-R > 6-R > 5-R > 2-S > 3-R > 4-R > 1-S > 2-R> cisplatin 321 
 322 
The coordination compound 7-R was associated with the highest cellular accumulation and this data was 323 
in line with the notable potency assessed for this compound (IC50 = 1.9 μM). The cationic 324 
cyclometallated compounds 5-R and 6-R (IC50 = 1.59 and 0.82 μM, respectively) exhibiting a high 325 
cytotoxic activity displayed a remarkable amount of platinum accumulated per cell. These results are in 326 
agreement with the elevated platinum cellular uptake described for cationic mononuclear58 and 327 
polynuclear71 platinum complexes with regard to cisplatin. The accumulation of complexes 5-R, 6-R 328 
and 7-R was about 10, 15 and 28 times higher than that of cisplatin, respectively. 329 
Concerning the neutral cycloplatinated complexes 1-R–4-R and 1-S–2-S, no correlation was observed 330 
between the antiproliferative efficacy in MDA-MB-231 breast cancer cells and the Pt cellular uptake. 331 
These data are in agreement with previous studies reporting that cell uptake per se, may not necessarily 332 
give an indication of the level of the antitumor activity.20,72 The relative contribution of cellular 333 




Eight cyclometallated platinum(II) compounds (1-R–6-R and 1-S–2-S) containing a chiral primary 338 
amine ligand [(R or S)-1- (1-naphthyl)ethylamine] and the coordination compound 7-R, containing two 339 
non-cyclometallated chiral (R) amines, were tested as new antitumor drugs. Complexes 3-R, 4-R, 6-R 340 
and 7-R were synthesized in this work and characterized by spectral and elemental analysis. The 341 
molecular structure of compound 7-R was solved by X-ray analysis. Cytotoxicity studies revealed the 342 
high effectiveness of either neutral cycloplatinated compounds (2-R and 2-S), cationic cycloplatinated 343 
compounds (5-R–6-R) or coordination compound (7-R) against human lung, breast and colon 344 
adenocarcinoma cell lines (A-549, MDA-MB-231, MCF-7 and HCT-116 respectively). In the cisplatin 345 
resistant HCT-116 colon cancer cells, neutral platinacycle 2-R (IC50 = 270 nM), and the ionic 346 
compounds containing the chelating diphosphine 5-R (IC50 = 1.8 μM), and 6-R (IC50 = 1.6 μM) were 347 
up to 148-, 22- and 25-fold more potent than when cisplatin is used as a positive control. Based on IC50 348 
data, the absolute configuration (R or S) of the cyclometallated ligand [1-(1-naphthyl)ethylamine] does 349 
not produce relevant differences in the biological properties of the two pairs of enantiomers 1-R vs. 1-S 350 
and 2-R vs. 2-S. 351 
Considering plausible target biomolecules for the studied compounds, the electrophoretic mobility of 352 
complexes of 2-R and 2-S indicates alteration of the DNA tertiary structure in a similar way as cisplatin, 353 
although at higher concentrations. Compounds 3-R–7-R were not efficient at all for removing the 354 
plasmid DNA supercoils. Among them, cationic platinacycle 5-R turned out to be a topoisomerase I 355 
inhibitor in a topoisomerase- based gel assay. All the compounds with the exception of neutral 356 
platinacycle 4-R, which was not cytotoxic in the antiproliferative assay, inhibited cathepsin B in a dose 357 
dependent manner. The coordination Pt(II) complex 7-R turned out to be the most potent (IC50 = 17 358 
μM) of the studied compounds inhibiting cathepsin B. As representative complexes of the series, 359 
platinacycles 2-R and 5-R (G-1 phase) and 6-R (S and G-2) were found to suppress A-549 lung cancer 360 
cell growth mainly through cell cycle arrest. Induction of apoptosis is also observed for compounds 2-R 361 
and 6-R. Further studies are in progress upon the studied complexes for both understanding structure–362 





Elemental analyses of C, H and N were performed with an Eager 1108 microanalyzer. NMR spectra 368 
were recorded in CDCl3 at 298 K with Mercury 400 (1H, 19F) and Bruker 400 Avance III HD (31P, 369 
195Pt) spectrometers. Chemical shifts are given in δ values (ppm) relative to SiMe4 (1H), CFCl3 (19F), 370 
85% H3PO4 (31P{1H}) and H2PtCl6 in D2O (195Pt), and coupling constants are given in Hz. 371 
Multiplicity is expressed as: s (singlet), d (doublet), t (triplet), and q (quadruplet). Compounds 1-R, 2-R 372 
and 5-R have been previously reported.30 373 
 374 




Preparation of the compounds 379 
Compound [PtCl{(R)-NH2CH(CH3)C10H6}{P(4-FC6H4)3}] (3-R) was obtained after stirring at room 380 
temperature for 2 hours a solution containing 50 mg (0.104 mmol) of compound 1-R and 33 mg (0.104 381 
mmol) of P(4-FC6H4)3 in 20 mL of acetone. The solvent was evaporated and the residue was treated 382 
with hexane. The white solid was filtered and dried under vacuum. Yield: 40 mg (53%). 1H NMR (400 383 
MHz, CDCl3), δ = 7.72–7.67 (m, 7H, Ho,PR3 + Hf or Hc), 7.61 (d, 3JH–H = 8.0, 1H, Hf or Hc), 7.40 (t, 384 
3JH–H = 8.0, 1H, Hd or He), 7.33 (t, 3JH–H = 8.0, 1H, Hd or He), 7.07–7.02 (m, 6H, Hm,PR3), 6.94 (d, 385 
3JH–H = 8.0, 1H, Hb), 6.62 (dd, 3JH–H = 8.0, 4JH–P = 2.8, 3JH–Pt = 52.0, 1H, Ha), 5.47 (q, 3JH–H = 386 
6.0, 3JH–Pt = 58.8, 1H, Hh), 4.62 (m, 1H, Hi), 4.15 (m, 1H, Hi), 1.91 (d, 3JH–H = 6.0, 3H, Hg).19F 387 
NMR (376.45 MHz, CDCl3), δ = −108.2 (m). 31P NMR (161.98 MHz, CDCl3), δ = 20.99 (s, 1JP–Pt = 388 
4344.3). 195Pt NMR (85.68 MHz, CDCl3), δ = −3973.8 (d, 1JP–Pt = 4352.5). EA (calc. for 389 
C30H24ClF3NPPt·H2O): C: 48.79% (49.02%); H: 3.73% (3.57%); N: 1.74% (1.91%). 390 
Compound [PtCl{(R)-NH2CH(CH3)C10H6}{PTA}] (4-R) was obtained after stirring at room 391 
temperature for 2 hours a solution containing 63 mg (0.131 mmol) of compound 1-R and 21 mg (0.134 392 
mmol) of P(CH2)3N3(CH2)3 (PTA) in 20 mL of acetone. Precipitation of a white solid was observed; 393 
the solid was filtered, washed with ether and dried under vacuum. Yield: 63 mg (86%). 1H NMR (400 394 
MHz, d6-dmso), δ = 7.73 (d, 3JH–H = 8.0, 1H), 7.69 (d, 3JH–H = 8.0, 1H), 7.49 (dd, 3JH–H = 8.0, 395 
4JH–H = 2.8, 1H, Hc or Hf ), 7.42 (d, 3JH–H = 8.0, 1H), 7.35 (t, 3JH–H = 7.2, 1H, Hd or He), 7.35 (t, 396 
3JH–H = 7.2, 1H, Hd or He), 6.00 (m, 1H, Hh), 5.09 (m, 1H, Hi), 4.97 (dd, 2JH–H = 10.8, 3JH–H = 2.8, 397 
1H, Hi), {4.52 (d, 2JH–H = 12.8, 3H), 4.41 (d, 2JH–H = 12.8, 3H), AB system, PCH2N}, {4.34 (d, 398 
2JH–H = 15.0, 3H), 4.27 (d, 2JH–H = 15.0, 3H), AB system, NCH2N}, 1.55 (d, 3JH–H = 6.0, 3H, Hg). 399 
31P NMR (161.98 MHz, d6-dmso), δ = −67.03 (s, 1JP–Pt = 3699.6). 195Pt NMR (85.68 MHz, d6-400 
dmso), δ = −3911.6 (d, 1JP–Pt = 3721.9). EA (calc. for C18H24ClN4PPt·H2O): C: 37.70% (37.54%); 401 
H: 4.72% (4.55%); N: 9.36% (9.73%). 402 
Compound [Pt{(R)-NH2CH(CH3)C10H6}{(C6F5)2PCH2CH2P- (C6F5)2}]Cl (6-R) was obtained after 403 
stirring at room temperature for 2 hours a solution containing 55 mg (0.115 mmol) of compound 1-R 404 
and 87 mg (0.115 mmol) of (C6F5)2PCH2CH2P- (C6F5)2 in 20 mL of acetone. The solvent was 405 
evaporated and the residue was treated with hexane. The white solid was filtered and dried under 406 
vacuum. Yield: 104 mg (78%). 1H NMR (400 MHz, CDCl3), δ = 7.72 (d, 3JH–H = 8.0, 1H, Hf or Hc), 407 
7.67 (dd, 3JH–H = 7.6, 4JH–H = 1.6, 1H, Hf or Hc), 7.43 (td, 3JH–H = 6.8, 4JH–H = 1.6, 1H, Hd or 408 
He), 7.41 (m, 1H, Hb), 7.39 (td, 3JH–H = 6.8, 4JH–H = 1.0, 1H, Hd or He), 7.30 (m, 1H, Ha), 5.99 (m, 409 
br, 3JH–Pt = 56.0, 1H, Hh), 5.80 (m, br, 2JH–Pt = 75.2, 2H, Hi), 3.28–2.96 (m, 2H); 2.70–2.68 (m, 1H); 410 
2.49–2.47 (m, br, 1H), 1.73 (d, 3JH–H = 6.4, 3H, Hg).19F NMR (376.45 MHz, CDCl3), δ = −124.20 411 
(m, 2F, Fo), −126.70 (m, 2F, Fo), −122.73 (d, 2JF–F = 18.9, 2F, Fo), −129.17 (d, 2F, 2JF–F = 15.0, Fo), 412 
−140.04 (t, 2JF–F = 20.7, 1F, Fp), −142.06 (t, 2JF–F = 18.9, 1F, Fp), −142.23 (t, 2JF–F = 20.7, 1F, Fp), 413 
−142.72 (t, 2JF–F = 20.7, 1F, Fp), −155.73 (t, 2JF–F = 18.9, 2F, Fm), −156.31 (t, 2JF–F = 18.9, 2F, 414 
Fm), −156.35 (t, 2JF–F = 18.9, 2F, Fm), −156.62 (t, 2JF–F = 18.9, 2F, Fm). 31P NMR (161.98 MHz, 415 
CDCl3), δ = 13.01 (d, 1JP–Pt = 1594.0, 2JPA–PB = 17.0, PA), 5.49 (d, 1JP–Pt = 3878.8, 2JPA–PB = 416 
17.0, PB). 195Pt NMR (85.68 MHz, CDCl3), δ = −4327.8 (dd, 1JPA–Pt = 3926.9, 1JPB–Pt = 1601.8). 417 
EA (calc. for C38H16ClF20NP2Pt·2H2O): C: 37.74% (38.19%); H: 1.82% (1.69%); N: 1.20% (1.17%). 418 
Compound [PtCl2{(R)-NH2CH(CH3)C10H6}2] (7-R) was obtained after stirring at room temperature 419 
for 4 days a mixture of 200 mg (0.48 mmol) of K2PtCl4 in 10 mL of water and 165 mg of (R)-420 
NH2CH(CH3)C10H6 (0.96 mmol) in 10 mL of methanol. The obtained solid was filtered, washed with 421 
water and extracted with dichloromethane (10 mL). The obtained solution was dried over MgSO4, and 422 
methanol was added. After cooling to 10 °C, a yellowish solid was obtained. Yield: 55 mg (46%). 1H 423 
NMR (400 MHz, CDCl3), δ = 8.34 (d, 3JH–H = 8.0, 1H), 7.86 (d, 3JH–H = 8.0, 1H), 7.80 (d, 3JH–H = 424 
8.0, 1H), 7.61 (td, 3JH–H = 8.0, 4JH–H = 1.6, 1H), 7.51 (td, 3JH–H = 8.0, 4JH–H = 1.6, 1H), 7.48 (d, 425 
3JH–H = 8.0, 1H), 7.46 (t, 3JH–H = 8.0, 1H), 5.23 (m, 1H, Hh), 3.95 (d, 2JH–H = 12.0, 1H, Hi), 3.68 (t, 426 
2JH–H = 12.0, 1H, Hi), 2.00 (d, 3JH–H = 6.8, 3H, Hg). 195Pt NMR (85.68 MHz, CDCl3), δ = −2179.0 427 
(s). EA (calc. for C24H26Cl2N2Pt·H2O): C: 45.67% (46.01%); H: 4.43% (4.50%); N: 4.37% (4.47%). 428 
Crystal data and structure refinement for 7-R. A yellow prism-like specimen of 7-R, grown in 429 
dichloromethane-methanol at room temperature, was used for the X-ray crystallographic analysis. X-ray 430 
intensity data were collected on a D8 VENTURE system equipped with a multilayer monochromator 431 
and a Mo microfocus (λ = 0.71073 Å) at 100 K and the structure was solved and refined using the 432 
Bruker SHELXTL software package.73 Further information is given in Table 5. 433 
Cell culture. Lung (A-549), colon (HCT-116) and breast (MCF-7 and MBA-MD-231) cancer cells were 434 
grown as a monolayer culture in minimum essential medium (DMEM with L-glutamine, without 435 
glucose and without sodium pyruvate) in the presence of 10% heat-inactivated fetal calf serum (FCS), 436 
10 mM D-glucose and 0.1% streptomycin/penicillin, under standard culture conditions (humidified air 437 
with 5% CO2 at 37 °C). 438 
Cell viability assay. For A-549 cell viability assays, compounds were suspended in high purity DMSO 439 
at 20 mM as stock solution. To obtain the final assay concentrations, they were diluted in DMEM 440 
(Dulbecco’s Modified Eagle Medium) (final concentration of DMSO was the same for all conditions, 441 
and was always lower than 1%). The assay was performed by a variation of the MTT (3-(4,5-442 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay described by Mosmann et al.74 and 443 
Matito and coworkers75 which is based on the ability of live cells to cleave the tetrazolium ring of the 444 
MTT thus producing formazan, which absorbs at 550 nm. In brief, 2.5 × 103 A-549 cells per well were 445 
cultured in 96 well plates for 24 hours prior to the addition of different compounds at different 446 
concentrations, in triplicate. After incubation for 72 h more, the medium was aspirated and 100 μL of 447 
filtered MTT (0.5 mg mL−1) were added to each well. Following 1 h of incubation with the MTT, the 448 
supernatant was removed and the precipitated formazan was dissolved in 100 μL DMSO. Relative cell 449 
viability, compared to the viability of untreated cells, was measured by absorbance at 550 nm on an 450 
ELISA plate reader (Tecan Sunrise MR20-301, TECAN, Salzburg, Austria). Concentrations that 451 
inhibited cell growth by 50% (IC50) after 72 h of treatment were subsequently calculated. 452 
For HCT-116, MDA-MB-231 and MCF-7 cell viability assays, a stock solution (50 mM) of each 453 
compound was prepared in high purity DMSO. Then, serial dilutions were made with DMSO/DMEM (1 454 
: 1) and finally a 1 : 500 dilution on culture medium was prepared. The final assay concentration of 455 
DMSO was the same in all experiments and was 0.2%. The assay was performed as described by Givens 456 
et al.76 HCT-116, MDA-MB-231 and MCF-7 cells were plated at 5000 cells per well, respectively, in 457 
100 μL media in tissue culture 96-well plates (Cultek). After 24 h, the media were replaced by a 100 μL 458 
per well of drug serial dilutions. Control wells did not contain the compounds under study. Each point 459 
concentration was run in triplicate. Reagent blanks, containing media and colorimetric reagent without 460 
cells were run on each plate. Blank values were subtracted from the test values and were routinely 5–461 
10% of the control values. Plates were incubated 72 h. Hexosaminidase activity was measured according 462 
to the following protocol. The media were removed and cells were washed once with PBS (phosphate-463 
buffered saline). 60 μL of substrate solution (p-nitrophenol-N-acetyl-β-D-glucosamide 7.5 mM, sodium 464 
citrate 0.1 M at pH 5.0, and 0.25% Triton X-100) was added to each well and incubated at 37 °C for 1–2 465 
hours. After this incubation time, a bright yellow colour appeared. Then, the plates were developed by 466 
adding 90 μL of the developer solution (glycine 50 mM, pH 10.4; EDTA 5 mM) and the absorbance was 467 
recorded at 410 nm. 468 
Cell cycle analysis. Cell cycle was assessed by flow cytometry using a fluorescence activated cell sorter 469 
(FACS). For this assay, 4 × 104 A-549 cells were seeded in 6 well plates with 2 mL of medium. After 470 
24 h of incubation, 2-R, 5-R, or 6-R was added at their IC50 values (9.3, 1.2 and 4.6 μM, respectively). 471 
Following 72 h of incubation, cells were harvested by mild tripsinization, collected by centrifugation 472 
and resuspended in Tris buffered saline (TBS) containing 50 mg mL−1 PI, 10 mg mL−1 DNase-free 473 
RNase and 0.1% Igepal CA-630. The cell suspension was incubated for 1 h at room temperature to 474 
allow for the staining of the cells with the PI, and afterwards FACS analysis was carried out at 488 nm 475 
in an Epics XL flow cytometer (Coulter Corporation, Hialeah, FL). Data from 1 × 104 cells were 476 
collected and analyzed using the Multicycle program (Phoenix Flow Systems, San Diego, CA). 477 
Apoptosis assay. Apoptosis was assessed evaluating the annexin-V binding to phosphatidylserine (PS), 478 
which is externalized early in the apoptotic process. 4 × 104 A-549 cells per well were seeded in 6 well 479 
plates with 2 mL of medium and treated as described above for the cell cycle analysis assay. After cell 480 
collection and centrifugation, cells were resuspended in 95 μL binding buffer (10 mM HEPES/NaOH, 481 
pH 7.4, 140 mM NaCl, 2.5 mM CaCl2). 3 μL of an Annexin-V FITC conjugate (1 mg mL−1) were then 482 
added and the suspension was incubated in the dark for 30 min, at room temperature. Just before FACS 483 
analysis, the cell suspension was added to a vial containing 500 μL of binding buffer, and then stained 484 
with 20 μL of 1 mg mL−1 PI solution. Data from 1 × 104 cells were collected and analyzed. 485 
Data analysis. For each compound, a minimum of three independent experiments with triplicate values 486 
to measure cell viability and a minimum of two independent experiments for cell cycle analysis and 487 
assessment of apoptosis were conducted. Data are given as the mean ± standard deviation (SD). 488 
DNA migration studies. A stock solution (10 mM) of each compound was prepared in high purity 489 
DMSO. Then, serial dilutions were made in MilliQ water (1 : 1). Plasmid pBluescript SK+ (Stratagene) 490 
was obtained using a QIAGEN plasmid midi kit as described by the manufacturer. Interaction of drugs 491 
with pBluescript SK+ plasmid DNA was analyzed by agarose gel electrophoresis following a 492 
modification of the method described by Abdullah et al.77 Plasmid DNA aliquots (40 μg mL−1) were 493 
incubated in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.5) with different concentrations of 494 
compounds 1-R–7-R and 1-S–2-S ranging from 0 μM to 200 μM at 37 °C for 24 h. The final DMSO 495 
concentration in the reactions was always lower than 1%. For comparison, cisplatin and ethidium 496 
bromide (EB) were used as reference controls. Aliquots of 20 μL of the incubated solutions containing 497 
0.8 μg of DNA were subjected to 1% agarose gel electrophoresis in TAE buffer (40 mM tris-acetate, 2 498 
mM EDTA, pH 8.0). The gel was stained in TAE buffer containing ethidium bromide (0.5 mg mL−1) 499 
and visualized and photographed under UV light.  500 
Topoisomerase I-based experiments were performed as described previously.78 Supercoiled pBluescript 501 
DNA, obtained as described above, was treated with topoisomerase I in the absence or presence of 502 
increasing concentrations of compounds 3-R–7-R. Assay mixtures contained supercoiled pBluescript 503 
DNA (0.8 μg), calf thymus topoisomerase I (3 units) and complexes 3-R–7-R (0–100 μM) in 20 μL of 504 
relaxation buffer Tris-HCl buffer (pH 7.5) containing 175 mM KCl, 5 mM MgCl2 and 0.1 mM EDTA. 505 
Ethidium bromide (EB, 10 μM) was used as a control of intercalating agents and etoposide (E, 100 μM) 506 
as a control of the non-intercalating agent. Reactions were incubated for 30 min at 37 °C and stopped by 507 
the addition of 2 μL of agarose gel loading buffer. Samples were then subjected to electrophoresis and 508 
DNA bands stained with ethidium bromide as described above. 509 
To distinguish whether compounds act as topoisomerase inhibitors or DNA intercalators the conversion 510 
of relaxed DNA to a supercoiled state caused by the compounds was analysed in the presence of 511 
topoisomerase I. Relaxed DNA was obtained by incubation of supercoiled DNA with topoisomerase I as 512 
described above. Assay mixtures (20 μL) contained: relaxed DNA, topoisomerase I (3 units) and 513 
compound (50 μM or 100 μM). Reactions were incubated 20 min at 37 °C and stopped as described 514 
above. Ethidium bromide (10 μM) was used as a control of intercalative drug. 515 
Cathepsin B inhibition assay. The colorimetric cathepsin B assay was performed as described by 516 
Casini et al.79 with few modifications. Briefly, the reaction mixture contained 100 mM sodium 517 
phosphate (pH 6.0), 1 mM EDTA and 200 μM sodium N-carbobenzoxy-L-lysine p-nitrophenyl ester as 518 
the substrate. To have the enzyme catalytically active before each experiment the cysteine in the active 519 
site was reduced by treatment with dithiothreitol (DTT). For this purpose, 5 mM DTT was added to the 520 
cathepsin B sample, before dilution, and incubated 1 h at 30 °C. To test the inhibitory effect of the 521 
platinum compounds on cathepsin B, activity measurements were performed in triplicate using fixed 522 
concentrations of enzyme (500 nM) and substrate (200 μM). The platinum compounds were used at 523 
concentrations ranging from 5 to 100 μM. Previous to the addition of substrate, cathepsin B was 524 
incubated with the different compounds at 25 °C for 2 h. The cysteine proteinase inhibitor E-64 was 525 
used as a positive control of cathepsin B inhibition. Complete inhibition was achieved at 10 μM 526 
concentration of E-64. Activity was measured over 90 s at 326 nm on a UV-spectrophotometer. 527 
Cell accumulation. Cell accumulation of platinum compounds was measured in MDA-MB-231. A total 528 
of 1 × 106 cells were seeded in 6 mm tissue culture dishes for 16 h in DMEMhigh glucose plus 10% 529 
FCS (fetal calf serum). Then, compounds were added at 50 μM for 4 h at 37 °C, 5% CO2. Cisplatin was 530 
used as a positive control at the same concentration, and DMSO as a vehicle control. After treatment, the 531 
cells were washed twice with PBS, tripsinized and harvested in PBS. The cell suspension was 532 
centrifuged and pellets were digested with 12 M HCl and diluted to 1.2 M HCl. Each treatment was 533 
done in duplicate. The samples were analyzed by ICPMS using an ICP-MS Perkin Elmer (Elan 6000). 534 
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.685 
Legends to figures 686 
 687 
Chart 1 Chemical structures of platinum-based anticancer drugs in clinical use. * Indicates a chiral 688 
center. 689 
 690 
Scheme 1 Synthesis of the studied compounds. 691 
 692 
Figure 1. Molecular structure of compound 7-R. Selected bond lengths (Å) and angles (°) with 693 
estimated standard deviations: Pt(01)–N(1): 2.065(3); Pt(01)–N(2): 2.072(3); Pt(01)–Cl(2): 2.2977(9); 694 
Pt(01)–Cl(1): 2.3106(8); N(1)–Pt(01)–N(2): 179.55(15); Cl(2)–Pt(01)–Cl(1): 178.28(3); N(1)–Pt(01)–695 
Cl(2): 87.90(9); N(2)–Pt(01)–Cl(2): 91.67(11); N(1)–Pt(01)–Cl(1): 91.22(10); N(2)–Pt(01)–Cl(1): 696 
89.22(9).. 697 
 698 
Figure 2. Comparison of the IC50 (μM) values obtained for the platinum(II) complexes 1-R–7-R, 1-S–699 
2-S and cisplatin in the A-549 (lung), MDA-MB-231 and MCF-7 (breast) and HCT-116 (colon) cancer 700 
cell lines. Compound 4-R (IC50 value >100) is not shown. 701 
 702 
Figure 3 The percentages of cell cycle distributions in A-549 cells are depicted in the histogram and 703 
represented as the cell number vs. the DNA content plot. The conditions include untreated cells (control) 704 
and those treated with compounds 2-R, 5-R and 6-R at concentrations equal to their IC50 values (9.6 705 
μM, 1.2 μM and 4.6 μM, respectively) for 72 h. The harvested cells were stained with PI (propidium 706 
iodide) and their DNA content analyzed by flow cytometry. 707 
 708 
Figure 4. The histogram shows the percentage variations of the quadrants depicting alive (Q4), early 709 
apoptotic (Q3) and late apoptotic/necrotic (Q2/Q1) phases in A-549 cells. The same is represented by 710 
the adjoining figure. The conditions include untreated cells (control) and those treated with compounds 711 
2-R, 5-R and 6-R at concentrations equal to their IC50 values (9.6 μM, 1.2 μM and 4.6 μM, 712 
respectively) for 72 h. 713 
 714 
Figure 5 Interaction of pBluescript SK+ plasmid DNA (0.8 μg) with increasing concentrations of 715 
compounds under study, cisplatin and ethidium bromide (EB). Lane 1: DNA only. Lane 2: 2.5 μM. Lane 716 
3: 5 μM. Lane 4: 10 μM. Lane 5: 25 μM. Lane 6: 50 μM. Lane 7: 100 μM. Lane 8: 200 μM; sc = 717 
supercoiled closed circular DNA; oc = open circular DNA. 718 
 719 
Figure 6 Analysis of 3-R–7-R as putative DNA intercalators or topoisomerase I inhibitors. Conversion 720 
of supercoiled pBluescript plasmid DNA (0.8 μg) to relaxed DNA by the action of topoisomerase I (3 721 
units) in the absence or in the presence of increasing amounts of compounds 3-R–7-R was analyzed by 722 
agarose gel. Ethidium bromide (EB) was used as a control of intercalating agent and etoposide (E) as a 723 
control of nonintercalating agent. Lane 1: (–) scDNA only. Lane 2: 0 μM drug. Lane 3: 10 μM drug. 724 
Lane 4: 25 μM drug. Lane 5: 100 μM drug. Except for lane 1, all lanes included topoisomerase I; sc = 725 
supercoiled closed circular DNA; oc = open circular DNA. 726 
 727 
Figure 7 Effect of compound 5-R on the activity of topoisomerase I. Lane 1, (–) scDNA as a control. 728 
Lane 2, relaxed DNA as a control. Relaxed pBluescript plasmid DNA was incubated with topoisomerase 729 
I (3 units) in the presence of 50 μM (lane 3) or 100 μM (lane 4) of compound 5-R and 10 μM (lane 5) of 730 
ethidium bromide (EB). The conversion of relaxed DNA to supercoiled DNA was analysed after a 20 731 
min incubation. Reaction containing EB is included as an example of an intercalative drug. sc = 732 





































































Table 3 IC50 (μM) values and % of residual activity of cathepsin B at 100 μM for compounds 1-R–7-R, 802 













Table 5 Crystallographic and refinement data for compound 7-R 816 
 817 
 818 
 819 
